



Fluence

Professional Education in Psychedelic-Assisted
Psychotherapy and Integration

OUR MISSION STATEMENT

To give healthcare providers the clinical skills and knowledge to provide effective, compassionate, evidence-based psychedelic therapy and integration services to patients through dynamic, interactive online and in-person trainings

LEADERSHIP TEAM



DR. INGMAR GORMAN
CO-FOUNDER & CEO

Dr. Ingmar Gorman is a psychologist and researcher who received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University. He simultaneously served as site co-principal investigator on an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist on the same study, as well as another FDA approved clinical trial of psilocybin for treatment resistant depression. Dr. Gorman has published on the topics of classic psychedelics, ketamine, MDMA, and Psychedelic Harm Reduction and Integration.



DR. ELIZABETH NIELSON
CO-FOUNDER & CHIEF VISIONARY OFFICER

Dr. Elizabeth Nielson is a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a Site Co-Principal Investigator and therapist for an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and has served as a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, psilocybin-assisted treatment of treatment resistant depression, and earlier phase 2 and 3 trials of MDMA-assisted psychotherapy. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists' personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.



MICHAEL KUNTZ
CHIEF OPERATING OFFICER

Michael Kuntz is a longtime digital media and advertising veteran, and recently served as COO of the USA Today Network (part of Gannett), where he oversaw the company's day-to-day operations, sales, marketing and corporate development. Prior to his time at USA Today, Michael was global SVP of Gawker Media, and formerly, Publisher & CRO at Hearst Magazines. In 2018, Michael turned to psychedelic-assisted therapy to successfully combat ongoing struggles with mental illness, and since, has invested in and advised several start-ups in the psychedelic community, including The Third Wave and Lucid News.

OUR FOCUS

GROWING MENTAL HEALTH CRISIS AND ITS TOLL ON SOCIETY

- **1 in 5** U.S. adults experience mental illness each year
- From August 2020 – February 2021, the percentage of U.S. adults with symptoms of an anxiety or depressive disorder increased to **41.5%**
- In 2019, **19.3 million** people aged 18 or over had a substance abuse disorder
- PTSD now affects **7.7 million** adults in the U.S.
- In an analysis completed before the COVID-19 pandemic, experts found that the U.S. would spend **\$238 billion** on direct mental health care in 2020

A DIFFERENT APPROACH TO TREATING MENTAL ILLNESS

- To address the widening gaps within today's mental health care system, many scientists and **researchers continue to produce data that points to psychedelics** – which have been used throughout history for medicinal purposes
- Rigorous clinical trials – paired with psychotherapy - using MDMA, psilocybin, and other psychedelic compounds continue to demonstrate their potential as **treatments for unmet needs** in mental health
- In combination with therapy, **psychedelics allow for a more person-centered, holistic approach** to working with individuals suffering from depression, anxiety, PTSD, substance use disorder and other forms of psychological distress
- As both psychedelic drugs and integration therapy continue to reshape the future of mental health care, training and education are paramount as **millions of therapists, prescribing clinicians, and healthcare professionals are not prepared to meet the future patient demand**

GAINING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING MENTAL HEALTH DISORDERS

- Johns Hopkins, Yale, University of California, Berkley, Mount Sinai, and NYU have recently established psychedelic research centers
- Psychedelic psychotherapy legalization initiatives are in motion across the United States, Canada and parts of Europe
- FDA grants "breakthrough therapy" status to psilocybin therapy for its potential to combat severe treatment-resistant depression
- First Phase 3 clinical trial conducted with psychedelic-assisted therapy found that MDMA paired with counseling brought marked relief to patients with severe post-traumatic stress disorder



A psychedelic drug boom in mental health treatment comes closer to reality

The New York Times

The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.

Forbes

Why The Future Of Mental Health Care May Lie In Psychedelics


RAPIDLY EXPANDING PSYCHEDELIC DRUGS MARKET

- The psychedelic drugs market is expected to reach **\$6.8 billion** by 2027, from \$2 billion in 2019
- Currently **30+** drug sponsors pursuing clinical trials of MDMA, psilocybin, LSD and other drug compounds
- 1,100 therapists have applied to MAPS for training, and over **15,000** have asked to be notified of training opportunities
- Projected bottleneck in the future dissemination of these treatments by drug development companies due to the **lack of trained therapists**

PSYCHEDELICS TAKE FLIGHT

Over the past decade, there has been an increase in clinical trials testing psilocybin, MDMA and LSD for use in psychiatric conditions, including depression, drug dependency and anorexia nervosa.

■ = 1 trial ■ Psilocybin ■ MDMA ■ LSD



Source: Nature.com, January 2021; Data Bridge; NY Times, April 2021

TOTAL ADDRESSABLE MARKETPLACE



Mental Health Professionals

1.3M licensed therapists in the U.S.

Fluence offers accessible, credentialed, professional trainings online and in-person to physicians and psychotherapists, and offers ongoing community networking



Wellness Practitioners

1.2M wellness professionals – counselors, coaches, etc

Fluence provides continuing education credits for coaches and welcomes wellness practitioners to the majority of its courses



Drug Developers

30+ psychedelic drug development companies pursuing clinical trials

Fluence delivers solutions through research design consulting, therapy manual writing, research therapist training, and post-approval provider training



Medical & Mental Health Institutions

12,000+ mental health facilities in need of basic training and education

Fluence has the staff and resources to deliver custom training packages for institutions to smoothly integrate high quality psychedelic healthcare

FLUENCE LIVES AT THE INTERSECTION OF PSYCHEDELIC MEDICINE


Experienced trainers conducting psychedelic research with multiple compounds for multiple drug sponsors

Bridging academia, industry, and community training & education dissemination

As a *neutral* entity, uniquely positioned to solve the training bottleneck problem in psychedelic medicine

Only company with a peer-reviewed model for psychedelic harm reduction and integration

Highly-regarded, trusted, and well-known within the industry



MEETING THE DEMAND FOR PSYCHEDELIC THERAPY TRAINING & EDUCATION

Fluence offers a scalable approach to training the next generation of clinicians, psychotherapists and wellness practitioners - with a goal of **training 25,000+ healthcare professionals over the next five years**. This includes psychedelic integration, ketamine, psilocybin, MDMA, and 5-MeO-DMT.



Understanding Ketamine Fall | Online

Learn principles for screening and preparing patients for ketamine treatment, and integrating the insights...

📅 Sep 11 - Sep 12, 2021

🕒 10:00 AM - 5:00PM EDT

👤 Dr. Casey Paleos, Dr. Ingmar ...




Psychedelic Integration: Premise and Promise Summer | Online

Fluence's foundational course is designed for those who want to learn about Psychedelic Harm Reduction and Integration...

📅 Jul 9 - Jul 11, 2021

🕒 9:00AM - 2:00 PM EDT

👤 Dr. Elizabeth Nielson, Dr. In...



Integrating Psychedelics with Evidence-Based Therapy, Fall 2021 | Online

This 12-week course is a diverse and challenging set of readings aimed toward deepening each student's...

📅 Sep 2 - Nov 18, 2021

🕒 5:30pm EDT

👤 Dr. Alan Davis




Integration Essentials, Fall 2021 | Online

A 14-week Reading and Study Group for therapists and healthcare providers

📅 Sep 8 - Dec 15, 2021

🕒 3:00 - 4:30pm ET

👤 Dr. Ingmar Gorman



Psychedelics and Psychoanalysis, Fall 2021 | Online

This Reading & Study Group uses contemporary and historical sources to teach the numerous ways psychoanalysis...

📅 Sep 22 - Dec 15, 2021

🕒 10:00 - 11:30 AM ET

👤 Dr. Jeffrey Guss

ESTABLISHED LEADERS IN THE FIELD, AND IN THE PRESS

TIME

Inside Ibogaine, One of the Most Promising
and Perilous Psychedelics for Addiction

Forbes

As More People Turn to Psychedelics, Integration
Proves a Crucial Factor For Breakthroughs

VICE

Therapists Are Unprepared to Talk to
People About Taking Psychedelics

GQ

The Case for Psychedelics Couples Counseling

DOUBLE BLIND

Why More Therapists Need to Learn About
Psychedelics -- Now

The New York Times

Can MDMA Save a Marriage?

*"PSYCHEDELICS CAN BE AS POWERFUL AS A SCALPEL TO A
SURGEON, AND THAT'S WHY THIS TRAINING IS SO IMPORTANT."*

- Dr. Ingmar Gorman

*"IT'S GOING TO BE A FIELD OF ITS OWN, AND TO SOME
EXTENT, IT IS ALREADY."*

- Dr. Elizabeth Nielson

OUR BUSINESS

SETTING THE FOUNDATION FOR A GROWING, PROFITABLE BUSINESS

January 2020 – December 2021

20+ PERSON TRAINING STAFF

Diverse group of researchers and licensed therapists with direct experience in psychedelic clinical trials

25+ COURSES & WORKSHOPS

Combination of online and in-person trainings, continuing education and accreditation for physicians, pharmacists, psychologists, social workers and coaches

900+ THERAPISTS TRAINED

Over \$10,000 awarded in diversity scholarships to improve equitable access to training

ENTERPRISE PARTNERSHIPS

Protocol design and custom training modules for drug development companies

\$750K+ SALES

On pace to surpass \$600,000 in 2021, resulting in a 318% year-over-year increase

NO OUTSIDE INVESTMENT

Self-funded to date. Currently pursuing seed financing

SERVICES, PRODUCTS, AND LEARNING SOLUTIONS

INDIVIDUAL TRAININGS

- Live Online Classes and Workshops
- OnDemand Content (Self-paced Learning)
- Psychedelic Therapy Certificate Programs

ENTERPRISE PARTNERSHIPS

- Consultation Services
- Psychotherapy Manual Design
- Therapist Cohort Training (Clinical Trials)

